Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Bioinformatics -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (53)	11/13/2001 12:37:16 AM
From: scaram(o)uche	Respond to of 80

Don't know BioCardia. Tom Quertermous is CFO. He is "father" of Del-1........... Monday November 12, 8:06 pm Eastern Time Press Release SOURCE: X-Mine Inc. X-Mine Announces Platform License and Collaboration Agreement with BioCardia BRISBANE, Calif.--(BW HealthWire)--Nov. 12, 2001--X-Mine Inc. announced today that it has entered into a licensing and collaboration agreement with BioCardia Inc. for X-Mine's data mining and knowledge discovery platform X-Miner. Terms of the agreement encompass early access to X-Mine's proprietary molecular pattern recognition and computational systems. ``We are very pleased to establish an early relationship with BioCardia which has eight clinical trials underway in three countries. This is an optimal validation of the ability of the X-Mine platform to open the bottleneck in multivariate data analysis and point results at therapeutics development and biomarker discovery, while significantly improving R&D organization efficiency,'' said X-Mine CEO Sandip Ray. X-Miner(TM) 1.0 is the first computational platform to provide an unrivaled suite of hi-performance molecular pattern recognition applications focused on supervised prediction and discovery for gene expression and proteomic data. Supervised tools are unique in their ability to predict outcomes with the support of a supervising vector that is derived from gene, tissue, survival time, drug, or other pre-existing information, and are central to in silico validation of therapeutic and other biological lead candidates emerging from genomics and other data-intensive biological research and development. ``BioCardia is excited about this agreement with X-Mine, because we believe that X-Mine has a world class team of experts and a state of the art platform which can provide us with a substantial competitive advantage,'' said BioCardia CEO Peter Altman. BioCardia is applying tools such as bioinformatics, custom DNA microarrays, and carefully designed clinical studies to understand biological pathways and explore health and disease. Ongoing efforts remain confidential, but they promise to present considerable advantages to patients suffering from disease through the identification of new strategies for patient care. For more information about BioCardia, please visit biocardia.com Founded by leaders in the field of genomics from MIT/Whitehead Institute, Stanford, and other leading universities, X-Mine is a genomic knowledge discovery company. X-Mine offers products and partnerships in molecular pattern recognition, information refinement, and custom development for predictive medicine, diagnostics and therapeutics. X-Mine products and partnerships address the single largest cost issue in drug discovery and development, namely, validation of product candidates early in the development process, enabling researchers to devote valuable time and resources to development of products most likely to impart real benefit for disease, in a reduced timeframe. For more information about X-Mine, please visit x-mine.com All statements in this press release that are not historical are forward-looking statements within the context of the U.S. securities laws. Such statements are based on current expectations that are subject to risks and uncertainties. Actual results may vary materially from those projected because of factors such including, but not limited to uncertainties relating to technologies, product development, manufacturing, market acceptance, cost or pricing of X-Mine products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, or patent protection and litigation. X-MINE expressly disclaims any obligation or undertaking to release publicly any updates, revisions or corrections to any forward-looking statements or historical information contained herein. X-Mine®, and X-Miner(TM) are registered trademarks of X-Mine Inc. in the United States and/or other countries, or X-Mine Inc. has filed applications for these trademarks in the United States and/or other countries. The names of actual companies and products mentioned herein may be the trademarks of their respective owners. Contact: X-Mine Inc., Brisbane Jeffrey Johnsen, 650/829-2614 jjohnsen@x-mine.com or BioCardia Inc., South San Francisco Peter Altman paltman@biocardia.com